University Medical Center Groningen
umcg.nlTotal trials
611
Active
154
Phase 3
31
Total enrollment
421,623
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| low dose tacrolimus in combination with everolimus | — | — | — | — | — | 1 | |
| standard dose tacrolimus with mycophenolate mofetil | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Invokana 300 mg and 100 mg | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Patiromer 8400 MG [Veltassa] | — | — | — | — | — | 1 | |
| 18F-FDG | — | — | — | — | — | 1 | |
| Leuprorelin | — | — | — | — | 2 | ||
| Finerenone | — | — | — | — | 2 | ||
| Dapagliflozin 10 mg/day | — | — | — | — | — | 1 | |
| Hydrochlorothiazide 25 mg | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | 4 | ||
| Dexamethasone | — | — | 5 | ||||
| Nivolumab | — | — | — | — | — | 2 | |
| Dapagliflozin | — | — | — | — | — | 2 | |
| Indocyanine Green | — | — | — | — | — | 1 | |
| Cetrelimab | — | — | — | — | — | 1 | |
| [18F]CETO tracer | — | — | — | — | — | 1 | |
| SC0062 strength 10mg | — | — | — | — | — | 1 | |
| SC0062 and dapagliflozin | — | — | — | — | — | 1 | |
| Medical Cannabis | — | — | — | — | — | 1 | |
| ARI-0001 | — | — | — | — | — | 1 | |
| Axi-cel | — | — | — | — | — | 1 | |
| Avastin | — | — | — | — | — | 1 | |
| Erbitux | — | — | — | — | — | 1 | |
| 25mg adalimumab-680LT and 15/25 mg risankizumab-800CW | — | — | — | — | — | 1 | |
| Adalimumab-680LT 25mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 15 mg/25 mg | — | — | — | — | — | 1 | |
| vicadrostat / empagliflozin combination 1 | — | — | — | — | — | 1 | |
| Spironolactone | — | — | — | — | — | 1 | |
| Risankizumab-800CW 4.5 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 15 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW 25 mg | — | — | — | — | — | 1 | |
| Risankizumab-800CW optimal dose | — | — | — | — | — | 1 | |
| injection with 15 mg bevacizumab-800CW before bronchoscopy | — | — | — | — | — | 1 | |
| injection with 25 mg bevacizumab-800CW before bronchoscopy | — | — | — | — | — | 1 | |
| Pembrolizumab Injection [Keytruda] | — | — | — | — | — | 1 | |
| MPDL3280A | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2021-06-04
- 2023-09-19
- 2025-02-06
- 2025-06
- 2025-06-01
- 2025-08
- 2025-09
- 2025-11
- 2025-12
- 2025-12-31
Top conditions
- Heart Failure18
- Breast Cancer16
- COPD12
- Melanoma12
- Esophageal Cancer11
- Cancer10
- Critical Illness10
- Asthma10
Frequently asked questions about University Medical Center Groningen
- How many clinical trials does University Medical Center Groningen have on ClinicalTrials.gov?
- University Medical Center Groningen is listed as the lead sponsor on 611 clinical trials in ClinicalTrials.gov, 154 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Medical Center Groningen's trials are in Phase 3?
- 31 of University Medical Center Groningen's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does University Medical Center Groningen focus on?
- University Medical Center Groningen's most-studied conditions on ClinicalTrials.gov are Heart Failure, Breast Cancer, COPD, Melanoma, Esophageal Cancer.
- When are University Medical Center Groningen's next clinical trial readouts?
- University Medical Center Groningen has 10 upcoming primary-completion readouts tracked here; the soonest is “Vaccination Against COVID-19 in Cancer”, expected around 2021-06-04.